Home|Journals|Articles by Year|Audio Abstracts
 

Original Article



Neuroprotective potential of Naringenin-loaded solid-lipid nanoparticles against rotenone-induced Parkinson’s disease model

Megala Mani, Shivaramakrishnan Balasubramanian, Kishore R. Manikandan, Balashanmugam Kulandaivel.




Abstract
Cited by 15 Articles

Currently available drug therapies are used to treat Parkinson’s disease (PD) by managing the clinical manifestations but not halt disease progression. Antioxidants as efficient organ-protective agents have been an integral part of human diet. Owing to the antioxidant’s chemical nature, crossing blood–brain barrier was a clinical challenge. Upon our initial screening of antioxidants by in silico and Drosophila studies, we identified Naringenin for studying its neuroprotective potential in rotenone (ROT)-induced PD rodent model. For better bioavailability in brain, Naringenin was loaded into solid-lipid nanoparticles (SLN) and evaluated. The results showed average particle size of 134.5 ± 20 nm, polydispersity index of 0.893, zeta potential of −11.9 mV, and entrapment efficiency of 89.87% ± 0.15%. In vitro release profile using dialysis technique follows the Higuchi model with the regression coefficient R2 of 0.9721. Neuroprotective activity of Naringenin–SLN was evaluated by ROT-induced PD rodent model. Results of behavioral observations and biomarkers provide an insight on the hypothesis that Naringenin as an SLN can exert neuroprotective effects, with the prospective to avert the progression of PD. Further studies are warranted in understanding the potential of antioxidants in the advanced delivery systems and to promote cost-effective large manufacturing of such formulations.

Key words: Parkinson’s disease, Oxidative stress, Antioxidants, Naringenin, Solid-lipid nanoparticles, Rotenone






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.